Approval · Notice of Compliance 17969 · 2016
NESINA: Notice of Compliance 17969
Issued April 6, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 17969
- Date
- April 6, 2016
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To add data from the completed examin cardiovascular outcomes trial in the product monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NESINA | Not yet assigned | — |
Medicinal ingredients
- ALOGLIPTIN BENZOATE 6.25 MG per TAB
- ALOGLIPTIN BENZOATE 12.5 MG per TAB
- ALOGLIPTIN BENZOATE 25 MG per TAB